AGIO Agios Pharmaceuticals
- 32.990
- -1.380-4.02%
Agios Pharmaceuticals所有资讯
TD Cowen维持Agios Pharmaceuticals(AGIO.US)买入评级
丰业银行维持Agios Pharmaceuticals(AGIO.US)买入评级，维持目标价75美元
RBC将Agios Pharmaceuticals的目标价从55美元上调至57美元，并维持其“跑赢大盘”评级。
agios pharmaceuticals被Scotiabank维持在板块表现评级
agios pharmaceuticals分析师评级
丰业银行维持Agios Pharmaceuticals(AGIO.US)买入评级，上调目标价至75美元
TD Cowen维持Agios Pharmaceuticals(AGIO.US)买入评级
Leerink Partners维持Agios Pharmaceuticals(AGIO.US)持有评级
RBC Capital重申对阿里拉姆制药的强劲表现，维持55美元的目标价格。
agios pharmaceuticals被Scotiabank评定为板块表现优异
美银证券维持Agios Pharmaceuticals(AGIO.US)买入评级
丰业银行维持Agios Pharmaceuticals(AGIO.US)买入评级，上调目标价至53美元
加皇资本市场维持Agios Pharmaceuticals(AGIO.US)买入评级，维持目标价55美元
TD Cowen维持Agios Pharmaceuticals(AGIO.US)买入评级
派杰投资维持Agios Pharmaceuticals(AGIO.US)买入评级，维持目标价56美元
Agios Pharma (AGIO) 获得买入评级来自派杰投资
agios pharmaceuticals在Scotiabank的板块中被评为行业外表现
Scotiabank宣布agios pharmaceuticals股票的目标价格为51.00美元/股。
Leerink Partners维持Agios Pharmaceuticals(AGIO.US)持有评级
瑞杰金融上调Agios Pharmaceuticals(AGIO.US)至买入评级，目标价51美元
暂无数据